A group of 11 heavily pretreated patients receiving low-dose thalidomide was compared with a similar group of 10 patients with refractory myeloma treated with a conventional oral chemotherapy. This study shows that thalidomide is not only effective in controlling the neoplastic clone but moreover, thanks to its low toxicity, allows out-patient management of these subjects.
|Number of pages||2|
|Publication status||Published - 2002|
- Refractory myeloma
ASJC Scopus subject areas